|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/22 Celldex Therapeutics, Inc. 10-Q 6/30/22 60:5.5M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.26M
2: EX-10.3 Material Contract HTML 29K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
11: R1 Document and Entity Information HTML 73K
12: R2 Condensed Consolidated Balance Sheets HTML 113K
13: R3 Condensed Consolidated Balance Sheets HTML 35K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 86K
and Comprehensive Loss
15: R5 Condensed Consolidated Statements of Cash Flow HTML 80K
16: R6 Basis of Presentation HTML 25K
17: R7 Significant Accounting Policies HTML 21K
18: R8 Fair Value Measurements HTML 96K
19: R9 Marketable Securities HTML 110K
20: R10 Intangible Assets HTML 20K
21: R11 Other Long-Term Liabilities HTML 36K
22: R12 Stockholders' Equity HTML 153K
23: R13 Stock-Based Compensation HTML 81K
24: R14 Accumulated Other Comprehensive Income HTML 40K
25: R15 Revenue HTML 23K
26: R16 Income Taxes HTML 22K
27: R17 Net Loss Per Share HTML 27K
28: R18 Kolltan Acquisition HTML 28K
29: R19 Significant Accounting Policies (Policies) HTML 20K
30: R20 Fair Value Measurements (Tables) HTML 95K
31: R21 Marketable Securities (Tables) HTML 108K
32: R22 Other Long-Term Liabilities (Tables) HTML 35K
33: R23 Stockholders' Equity (Tables) HTML 148K
34: R24 Stock-Based Compensation (Tables) HTML 84K
35: R25 Accumulated Other Comprehensive Income (Tables) HTML 39K
36: R26 Net Loss Per Share (Tables) HTML 26K
37: R27 Basis of Presentation (Details) HTML 30K
38: R28 Fair Value Measurements (Details) HTML 45K
39: R29 Fair Value Measurements - Contingent Consideration HTML 26K
Liabilities (Details)
40: R30 Fair Value Measurements - Additional information HTML 29K
(Details)
41: R31 Marketable Securities (Details) HTML 58K
42: R32 Marketable Securities - Additional Information HTML 21K
(Details)
43: R33 Intangible Assets (Details) HTML 19K
44: R34 Other Long-Term Liabilities (Details) HTML 32K
45: R35 Other Long-Term Liabilities- New Jersey tax HTML 26K
benefits (Details)
46: R36 Stockholders' Equity (Details) HTML 60K
47: R37 Stock-Based Compensation - Stock Option Activity HTML 64K
(Details)
48: R38 Stock-Based Compensation - Employee Stock Option HTML 29K
and Incentive Plan Activity Additional Information
(Details)
49: R39 Stock-Based Compensation - Expenses (Details) HTML 24K
50: R40 Stock-Based Compensation - Valuation (Details) HTML 32K
51: R41 Accumulated Other Comprehensive Income (Details) HTML 38K
52: R42 Revenue (Details) HTML 38K
53: R43 Income Taxes (Details) HTML 19K
54: R44 Net Loss Per Share (Details) HTML 22K
55: R45 Kolltan Acquisition (Details) HTML 39K
58: XML IDEA XML File -- Filing Summary XML 103K
56: XML XBRL Instance -- cldx-20220630x10q_htm XML 1.45M
57: EXCEL IDEA Workbook of Financial Reports XLSX 82K
7: EX-101.CAL XBRL Calculations -- cldx-20220630_cal XML 114K
8: EX-101.DEF XBRL Definitions -- cldx-20220630_def XML 327K
9: EX-101.LAB XBRL Labels -- cldx-20220630_lab XML 756K
10: EX-101.PRE XBRL Presentations -- cldx-20220630_pre XML 529K
6: EX-101.SCH XBRL Schema -- cldx-20220630 XSD 94K
59: JSON XBRL Instance as JSON Data -- MetaLinks 248± 387K
60: ZIP XBRL Zipped Folder -- 0001104659-22-087222-xbrl Zip 221K
Exhibit 31.2
CERTIFICATION
I, Sam Martin, certify that:
1. | I have reviewed this report on Form 10-Q of Celldex Therapeutics, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 8, 2022 | By: | /s/ SAM MARTIN |
| Name: | |
| Title: | Senior Vice President and Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/8/22 | 8-K | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 Celldex Therapeutics, Inc. 10-K 12/31/23 87:8.5M Toppan Merrill/FA2 2/28/23 Celldex Therapeutics, Inc. 10-K 12/31/22 85:8.1M Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/18/22 Celldex Therapeutics, Inc. 8-K:1,9 7/15/22 11:257K Toppan Merrill/FA 6/23/22 Celldex Therapeutics, Inc. 8-K:1,2,9 6/20/22 11:225K Toppan Merrill/FA |